Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
Stopped Change in treatment priorities for these disease types as well as staffing concerns.
Conditions
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
- Classical Hodgkin Lymphoma
- Anaplastic Large Cell Lymphoma
- CD30+ Peripheral T-cell Lymphoma
Interventions
- DRUG: Brentuximab Vedotin
- DRUG: TAK228
- DEVICE: Glucose Monitor
Sponsor
M.D. Anderson Cancer Center
Collaborators